General Information of Drug (ID: DMQCW7V)

Drug Name
Tanaproget Drug Info
Synonyms
Tanaproget; 304853-42-7; NSP-989; UNII-W9F9H8GXWR; W9F9H8GXWR; 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile; T98; Tanaproget [USAN:INN]; 1zuc; NSP 989; Tanaproget (USAN/INN); AC1NA08O; SCHEMBL62188; CHEMBL539163; GTPL7416; DTXSID00184556; PYVFWTPEBMRKSR-UHFFFAOYSA-N; ZINC6245719; BDBM50375821; AKOS030526776; SB17247; DB04787; CS-1550; NSP-989;NSP 989;NSP989; HY-15606; KB-145966; FT-0735521; W-5758; D06003
Indication
Disease Entry ICD 11 Status REF
Estrogen deficiency FB83.0Y Investigative [1]
Cross-matching ID
PubChem CID
4369524
CAS Number
CAS 304853-42-7
TTD Drug ID
DMQCW7V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug(s) Targeting Progesterone receptor (PGR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Premature labour JB00 Approved [3]
Desogestrel DM27U4Y Contraception QA21 Approved [4]
Ulipristal DMBNI20 Contraception QA21 Approved [5]
Etonogestrel DMKA8J4 Contraception QA21 Approved [6]
Megestrol DMDH9KX Breast cancer 2C60-2C65 Approved [7]
Segesterone acetate; ethinyl estradiol DMFEGB0 Contraception QA21 Approved [8]
Norgestimate DMYP4XC Contraception QA21 Approved [6]
Dydrogesterone DMAKIDV Menstrual disorder GA20.3 Approved [9]
Medroxyprogesterone DMBGWPH Solid tumour/cancer 2A00-2F9Z Approved [9]
Ethynodiol diacetate DMZM84R Contraception QA21 Approved [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7416).
2 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
3 Clinical pipeline report, company report or official report of lipocine.
4 Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
7 Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
8 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
9 Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
10 Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.